What is Hexarelin Acetate and how does it differ from other GH secretagogues in potency and cardioprotective effects?

Hexarelin is a synthetic hexapeptide growth hormone secretagogue receptor (GHSR1a/ghrelin receptor) agonist with sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, distinguished by exceptionally high potency for GH release and unique cardiovascular effects beyond GH stimulation. While structurally related to GHRP-6 and Ipamorelin, Hexarelin demonstrates 10-100 fold greater GH secretory potency (EC50 in picomolar-to-low nanomolar range vs nanomolar for other GHRPs) attributed to the D-2-methyl-tryptophan at position 2 creating optimal GHSR1a binding pocket interactions. Mechanistically, Hexarelin binds GHSR1a on pituitary somatotrophs triggering Gq-protein-mediated phospholipase C activation producing IP3/DAG second messengers mobilizing intracellular Ca2+ and activating protein kinase C stimulating GH vesicle exocytosis. Uniquely, Hexarelin also demonstrates cardioprotective properties independent of GH - binding CD36 scavenger receptors on cardiomyocytes triggering PI3K-AKT-eNOS pathway activation promoting nitric oxide production, reducing oxidative stress, and protecting against ischemia-reperfusion injury. Research applications include high-potency GH secretagogue pharmacology, GHSR1a receptor biology, cardiovascular protection mechanisms investigating CD36 signaling, myocardial ischemia research, comparative GH secretagogue structure-activity relationships, and dual GHSR1a/CD36 pathway investigations.

How does Hexarelin's cardioprotective activity occur independently of GH secretion?

Hexarelin possesses unique cardiovascular benefits unrelated to growth hormone - binding CD36 scavenger receptors highly expressed on cardiomyocytes, vascular endothelium, and macrophages. CD36 activation by Hexarelin triggers: (1) PI3K-AKT signaling cascade phosphorylating endothelial nitric oxide synthase (eNOS) increasing NO production causing vasodilation and improved myocardial perfusion, (2) Mitochondrial protection - reducing reactive oxygen species (ROS) generation and preserving mitochondrial membrane potential during oxidative stress preventing cardiomyocyte apoptosis, (3) Anti-apoptotic signaling - activating survival pathways (AKT, ERK1/2) inhibiting pro-apoptotic proteins (Bad, caspase-3) protecting cardiomyocytes from ischemia-reperfusion injury, (4) Anti-inflammatory effects - modulating macrophage CD36 signaling reducing inflammatory cytokine production (TNF-α, IL-6) limiting cardiac inflammation after injury, (5) Calcium homeostasis regulation - modulating sarcoplasmic reticulum Ca2+ handling improving contractility and preventing arrhythmias. Evidence for GH-independence: CD36 knockout mice lose Hexarelin's cardioprotection while retaining GH secretion, GHSR1a antagonists block GH release but not cardiac protection, and non-GH-releasing Hexarelin analogs retain cardioprotective activity. Research applications include myocardial ischemia models, heart failure biology, ischemia-reperfusion injury mechanisms, CD36 receptor pharmacology, cardioprotective drug development, and dissecting GH-dependent vs GH-independent metabolic/cardiovascular effects.

What purity and quality standards does your Hexarelin Acetate meet for research?

Our Hexarelin Acetate exceeds >98% purity verified by reverse-phase HPLC demonstrating retention time characteristic of the His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 hexapeptide sequence. Each batch undergoes comprehensive quality control: mass spectrometry confirmation of molecular weight (~887 Da for acetate salt) validating complete sequence including D-2-methyl-tryptophan (unusual amino acid critical for high potency), C-terminal amidation, and acetate counterion, peptide sequencing via Edman degradation or MS/MS fragmentation verifying each residue and stereochemistry confirming D-2-methyl-Trp and D-Phe configurations essential for GHSR1a selectivity and potency, GHSR1a receptor binding bioassays using ghrelin receptor-expressing cells measuring Hexarelin's competitive displacement of ghrelin with IC50 quantification (typically 0.1-10 nM affinity demonstrating high-potency binding), functional GH secretion assays treating primary pituitary somatotroph cultures with dose-escalating Hexarelin measuring GH release via ELISA/chemiluminescence quantifying EC50 potency (picomolar-to-low nanomolar range, 10-100 fold more potent than GHRP-6 validating exceptional bioactivity), CD36 binding assays using cardiomyocytes or CD36-expressing cell lines confirming dual receptor recognition beyond GHSR1a, cardioprotective bioassays measuring cardiomyocyte viability under oxidative stress (H2O2 treatment) or hypoxia demonstrating Hexarelin's protective effects via MTT/LDH assays, calcium mobilization assays demonstrating Gq-PLC-IP3-Ca2+ pathway activation, endotoxin testing (<0.1 EU/mg), and comprehensive Certificate of Analysis.

What research applications benefit from Hexarelin's high potency and dual receptor activity?

Hexarelin excels in research requiring: high-potency GH secretagogue studies investigating structure-activity relationships - comparing Hexarelin's D-2-methyl-Trp substitution vs other GHRPs revealing molecular determinants of GHSR1a binding affinity and efficacy; cardiovascular protection research using myocardial ischemia-reperfusion models studying CD36-mediated cardioprotection, nitric oxide signaling, oxidative stress reduction, and anti-apoptotic pathways independent of GH; heart failure biology examining Hexarelin's effects on cardiac contractility, remodeling, and survival signaling through dual GHSR1a/CD36 activation; comparative GH secretagogue pharmacology evaluating Hexarelin vs GHRP-6 vs Ipamorelin vs Sermorelin for potency, receptor selectivity, and off-target effects; dose-response characterization where Hexarelin's high potency enables studying ultra-low concentration effects on GHSR1a signaling cascade activation; dual receptor pathway research dissecting GHSR1a (GH secretion, metabolic effects) from CD36 (cardiovascular protection, lipid metabolism) contributions to overall biological responses; pharmaceutical development of next-generation GH secretagogues or cardioprotective agents optimizing potency and tissue selectivity; metabolic-cardiovascular interface studies investigating how GH elevation (via GHSR1a) interacts with cardiac protection (via CD36) in metabolic syndrome or diabetes models; and aging research where Hexarelin's combined GH restoration plus cardioprotection may address multiple age-related declines simultaneously.

How should Hexarelin Acetate be stored and reconstituted for research use?

Store lyophilized Hexarelin Acetate at -20°C in original sealed vials for 24+ months stability. The lyophilized hexapeptide containing D-2-methyl-tryptophan and C-terminal amide remains stable when dry and frozen - protect from moisture and light (acetate salt hygroscopic). Reconstitute using sterile water, bacteriostatic water (0.9% benzyl alcohol), or dilute acetic acid solution slowly down vial wall, then gently swirl (never shake) until completely dissolved at typical concentration 0.1-5 mg/mL (Hexarelin's high potency enables lower working concentrations). Allow 2-3 minutes for complete dissolution. Refrigerate reconstituted solution at 2-8°C and use within 14-21 days for maximum bioactivity - peptides in aqueous solution degrade via tryptophan oxidation (Hexarelin contains two Trp residues susceptible to oxidation), deamidation, and aggregation. For optimal stability reconstitute in slightly acidic pH (5-6) and protect from light as tryptophan photodegrades under UV exposure. Avoid repeated freeze-thaw cycles causing peptide aggregation and loss of receptor binding - for multi-week protocols aliquot reconstituted solution into single-use sterile amber vials immediately after reconstitution storing aliquots at -20°C wrapped in foil. Thaw fresh aliquot for each experiment accepting one freeze-thaw. Due to high potency, prepare serial dilutions carefully to achieve desired concentrations for dose-response studies.

Why is Hexarelin 10-100 fold more potent than other GH secretagogues?

Hexarelin's exceptional potency (EC50 for GH release: picomolar-to-low nanomolar vs nanomolar-to-micromolar for other GHRPs) derives from the D-2-methyl-tryptophan substitution at position 2. Structural analysis reveals: (1) The indole side chain of D-2-methyl-Trp creates optimal hydrophobic and π-π stacking interactions within the GHSR1a binding pocket - the methyl group at position 2 of the indole ring enhances binding affinity by filling a hydrophobic cavity in the receptor creating additional van der Waals contacts. (2) D-stereochemistry at position 2 orients the methylated indole for maximal receptor interaction vs L-isomers which position side chains suboptimally. (3) Constrained peptide backbone from D-amino acids (D-2-methyl-Trp, D-Phe) reduces conformational flexibility locking Hexarelin in bioactive conformation reducing entropic penalty upon receptor binding. (4) Synergistic contributions from multiple aromatic residues (His1, D-2-methyl-Trp2, Trp4, D-Phe5) creating extensive aromatic interaction network with GHSR1a transmembrane helices. (5) Enhanced receptor activation efficacy - Hexarelin not only binds with higher affinity but also demonstrates superior intrinsic efficacy (agonist efficacy) producing maximal G-protein activation and downstream signaling at lower receptor occupancy. Research applications: structure-activity relationship studies identifying binding determinants, molecular dynamics simulations mapping receptor-ligand interactions, comparative pharmacology establishing potency hierarchies, and pharmaceutical optimization of GH secretagogue design.

What dosage specifications and bulk pricing are available for Hexarelin Acetate?

We offer two Hexarelin Acetate specifications: HX2 (2mg per 10-vial kit), HX5 (5mg per 10-vial kit). Pricing with bulk discounts: HX2: $70/kit (1 kit), $65/kit (20+ kits = 7.1% discount), $60/kit (50+ kits = 14% discount). HX5: $160/kit (1 kit), $150/kit (20+ kits = 6.3% discount), $145/kit (50+ kits = 9.4% discount). The two concentration options accommodate diverse research from pilot GHSR1a binding and high-potency dose-response characterization (lower concentrations suitable given Hexarelin's picomolar-nanomolar potency) to extensive cardiovascular protection studies and chronic GH axis modulation protocols (higher concentrations for animal models or large-scale experiments). Pricing reflects synthesis complexity of the hexapeptide requiring incorporation of D-2-methyl-tryptophan (non-standard amino acid requiring specialized synthesis), stereochemical control ensuring D-configuration at positions 2 and 5 (critical for potency and selectivity), C-terminal amidation essential for bioactivity, rigorous quality control (HPLC purity, mass spec confirming D-2-methyl-Trp incorporation, GHSR1a binding assays validating high-affinity recognition, GH secretion bioassays confirming exceptional potency EC50 values, CD36 binding/cardioprotection assays validating dual receptor activity, calcium mobilization assays), and comprehensive CoA documentation while maintaining >98% purity essential for reproducible high-potency GH secretagogue and cardioprotective research. Bulk discounts support multi-year cardiovascular-metabolic research programs, institutional facilities, pharmaceutical GH secretagogue or cardioprotective drug development, and international research consortia. Contact via WhatsApp for custom quantities.

How do you validate Hexarelin's high potency GH secretion and cardioprotective activity?

Beyond chemical purity (HPLC >98%, mass spec confirming D-2-methyl-Trp-containing hexapeptide with amidation), we employ comprehensive potency and functional validation: (1) High-affinity GHSR1a binding - competitive displacement assays using ghrelin receptor-expressing cells measuring IC50 typically 0.1-10 nM (10-100 fold higher affinity than GHRP-6) confirming exceptional receptor recognition. (2) High-potency GH secretion bioassays - treating primary pituitary somatotroph cultures with picomolar-to-nanomolar Hexarelin concentrations measuring GH release via ultra-sensitive ELISA/chemiluminescence quantifying EC50 values (typically 10-1000 picomolar range) demonstrating 10-100 fold greater potency vs other GHRPs validating the D-2-methyl-Trp contribution. (3) Dose-response curve comparison - side-by-side testing Hexarelin vs GHRP-6 vs Ipamorelin showing leftward shift of Hexarelin curve (lower EC50) confirming superior potency. (4) CD36 binding assays - using cardiomyocytes, endothelial cells, or recombinant CD36 measuring Hexarelin binding via competition assays or surface plasmon resonance demonstrating dual receptor recognition. (5) Cardioprotective bioassays - treating cardiomyocytes with H2O2 (oxidative stress), hypoxia, or ischemia-reperfusion and measuring viability (MTT assay), LDH release (membrane integrity), caspase-3 activity (apoptosis), and ROS generation showing Hexarelin dose-dependently reduces injury. (6) Nitric oxide production - measuring eNOS phosphorylation via Western blot and NO release (DAF fluorescence or Griess assay) in endothelial cells confirming CD36-PI3K-AKT-eNOS pathway activation. (7) Mitochondrial protection assays - measuring mitochondrial membrane potential (JC-1 dye), ROS generation (DHE fluorescence), and ATP production demonstrating Hexarelin preserves mitochondrial function under stress. (8) GH-independence validation - demonstrating cardioprotection persists with GHSR1a antagonists or in GHSR1a knockout cells confirming CD36-mediated effects.

Can Hexarelin be used in combination with GHRH analogs or cardiovascular agents?

Yes! Hexarelin combinations enable multi-faceted research: (1) Hexarelin + GHRH analogs (Sermorelin, CJC-1295, Tesamorelin) - dual GHSR1a/GHRHR activation produces synergistic GH release through convergent Ca2+/cAMP pathways as previously described. Given Hexarelin's exceptional potency, lower doses can be used in combination protocols achieving maximal GH secretion while minimizing off-target effects. (2) Hexarelin + exogenous GH - combining pulsatile GH secretagogue stimulation with continuous exogenous GH reveals differences in metabolic/anabolic responses to pulsatile vs sustained GH exposure. (3) Hexarelin + nitric oxide donors (SNP, SNAP) or eNOS modulators - investigating synergistic cardioprotection from dual NO-enhancing mechanisms (Hexarelin's CD36-eNOS activation plus exogenous NO donors) in ischemia-reperfusion models. (4) Hexarelin + antioxidants (NAC, vitamin E) - examining additive protection against oxidative cardiac injury combining Hexarelin's mitochondrial ROS reduction with chemical antioxidant scavenging. (5) Hexarelin + PI3K/AKT pathway modulators - dissecting CD36 signaling mechanisms using PI3K inhibitors (wortmannin, LY294002) or AKT activators in combination with Hexarelin demonstrating pathway dependence of cardioprotection. (6) Hexarelin + ischemic preconditioning - investigating whether pharmacological CD36 activation (Hexarelin) mimics or enhances endogenous ischemic preconditioning cardioprotection. (7) Hexarelin + beta-blockers or ACE inhibitors - examining cardiovascular drug interactions in heart failure models. (8) Hexarelin + metabolic substrates - combining GH secretagogue effects with specific fuel availability (fatty acids, glucose, ketones) investigating metabolic flexibility. These combinations reveal pathway interactions, synergistic mechanisms, and translational therapeutic strategies.

What documentation and international shipping support Hexarelin research globally?

We ship Hexarelin Acetate in lyophilized form with cold pack insulation in sealed packaging protecting the high-potency hexapeptide. Lyophilized peptide remains stable at ambient temperature for short periods (up to 7 days) but cold packs minimize degradation during transit. International delivery typically takes 10-14 days with tracking; immediately transfer to -20°C storage upon arrival. Each batch includes comprehensive Certificate of Analysis: HPLC chromatogram demonstrating >98% purity with retention time characteristic of the D-2-methyl-Trp-containing hexapeptide, mass spectrometry data confirming molecular weight (~887 Da acetate salt) validating complete sequence including D-2-methyl-tryptophan incorporation and C-terminal amidation, peptide sequencing verification via MS/MS or Edman degradation confirming each residue and stereochemistry, GHSR1a receptor binding data showing high-affinity ghrelin displacement with IC50 quantification (0.1-10 nM demonstrating exceptional binding), GH secretion bioassay dose-response curves using primary pituitary cells with EC50 quantification (picomolar-to-low nanomolar range confirming 10-100 fold greater potency vs other GHRPs), CD36 binding assay results demonstrating dual receptor recognition, cardioprotective bioassay data measuring cardiomyocyte viability under oxidative stress or hypoxia showing dose-dependent protection, eNOS phosphorylation and NO production data confirming CD36-PI3K-AKT-eNOS pathway activation, mitochondrial protection assay results, endotoxin testing (<0.1 EU/mg), batch number and manufacturing date. This documentation satisfies institutional requirements worldwide ensuring compliance for high-potency GH secretagogue research, cardiovascular protection studies, and dual GHSR1a/CD36 pharmacology investigations across global research institutions.

Home ProductsHexarelin Acetate

Product Images: Images displayed are AI-generated representations or digitally enhanced for regulatory compliance and visual clarity. Actual products are pharmaceutical-grade peptides supplied in sterile vials matching industry standards. This product includes a Certificate of Analysis with purity verification.

HEX2

Hexarelin Acetate

Q: What research applications benefit from Hexarelin's high potency and dual receptor activity?

Hexarelin excels in research requiring: high-potency GH secretagogue studies investigating structure-activity relationships - comparing Hexarelin's D-2-methyl-Trp substitution vs other GHRPs revealing molecular determinants of GHSR1a binding affinity and efficacy; cardiovascular protection research using myocardial ischemia-reperfusion models studying CD36-mediated cardioprotection, nitric oxide signaling, oxidative stress reduction, and anti-apoptotic pathways independent of GH; heart failure biology examining Hexarelin's effects on cardiac contractility, remodeling, and survival signaling through dual GHSR1a/CD36 activation; comparative GH secretagogue pharmacology evaluating Hexarelin vs GHRP-6 vs Ipamorelin vs Sermorelin for potency, receptor selectivity, and off-target effects; dose-response characterization where Hexarelin's high potency enables studying ultra-low concentration effects on GHSR1a signaling cascade activation; dual receptor pathway research dissecting GHSR1a (GH secretion, metabolic effects) from CD36 (cardiovascular protection, lipid metabolism) contributions to overall biological responses; pharmaceutical development of next-generation GH secretagogues or cardioprotective agents optimizing potency and tissue selectivity; metabolic-cardiovascular interface studies investigating how GH elevation (via GHSR1a) interacts with cardiac protection (via CD36) in metabolic syndrome or diabetes models; and aging research where Hexarelin's combined GH restoration plus cardioprotection may address multiple age-related declines simultaneously.

Q: How should Hexarelin Acetate be stored and reconstituted for research use?

Store lyophilized Hexarelin Acetate at -20°C in original sealed vials for 24+ months stability. The lyophilized hexapeptide containing D-2-methyl-tryptophan and C-terminal amide remains stable when dry and frozen - protect from moisture and light (acetate salt hygroscopic). Reconstitute using sterile water, bacteriostatic water (0.9% benzyl alcohol), or dilute acetic acid solution slowly down vial wall, then gently swirl (never shake) until completely dissolved at typical concentration 0.1-5 mg/mL (Hexarelin's high potency enables lower working concentrations). Allow 2-3 minutes for complete dissolution. Refrigerate reconstituted solution at 2-8°C and use within 14-21 days for maximum bioactivity - peptides in aqueous solution degrade via tryptophan oxidation (Hexarelin contains two Trp residues susceptible to oxidation), deamidation, and aggregation. For optimal stability reconstitute in slightly acidic pH (5-6) and protect from light as tryptophan photodegrades under UV exposure. Avoid repeated freeze-thaw cycles causing peptide aggregation and loss of receptor binding - for multi-week protocols aliquot reconstituted solution into single-use sterile amber vials immediately after reconstitution storing aliquots at -20°C wrapped in foil. Thaw fresh aliquot for each experiment accepting one freeze-thaw. Due to high potency, prepare serial dilutions carefully to achieve desired concentrations for dose-response studies.

Q: Why is Hexarelin 10-100 fold more potent than other GH secretagogues?

Hexarelin's exceptional potency (EC50 for GH release: picomolar-to-low nanomolar vs nanomolar-to-micromolar for other GHRPs) derives from the D-2-methyl-tryptophan substitution at position 2. Structural analysis reveals: (1) The indole side chain of D-2-methyl-Trp creates optimal hydrophobic and π-π stacking interactions within the GHSR1a binding pocket - the methyl group at position 2 of the indole ring enhances binding affinity by filling a hydrophobic cavity in the receptor creating additional van der Waals contacts. (2) D-stereochemistry at position 2 orients the methylated indole for maximal receptor interaction vs L-isomers which position side chains suboptimally. (3) Constrained peptide backbone from D-amino acids (D-2-methyl-Trp, D-Phe) reduces conformational flexibility locking Hexarelin in bioactive conformation reducing entropic penalty upon receptor binding. (4) Synergistic contributions from multiple aromatic residues (His1, D-2-methyl-Trp2, Trp4, D-Phe5) creating extensive aromatic interaction network with GHSR1a transmembrane helices. (5) Enhanced receptor activation efficacy - Hexarelin not only binds with higher affinity but also demonstrates superior intrinsic efficacy (agonist efficacy) producing maximal G-protein activation and downstream signaling at lower receptor occupancy. Research applications: structure-activity relationship studies identifying binding determinants, molecular dynamics simulations mapping receptor-ligand interactions, comparative pharmacology establishing potency hierarchies, and pharmaceutical optimization of GH secretagogue design.

Q: What dosage specifications and bulk pricing are available for Hexarelin Acetate?

We offer two Hexarelin Acetate specifications: HX2 (2mg per 10-vial kit), HX5 (5mg per 10-vial kit). Pricing with bulk discounts: HX2: $70/kit (1 kit), $65/kit (20+ kits = 7.1% discount), $60/kit (50+ kits = 14% discount). HX5: $160/kit (1 kit), $150/kit (20+ kits = 6.3% discount), $145/kit (50+ kits = 9.4% discount). The two concentration options accommodate diverse research from pilot GHSR1a binding and high-potency dose-response characterization (lower concentrations suitable given Hexarelin's picomolar-nanomolar potency) to extensive cardiovascular protection studies and chronic GH axis modulation protocols (higher concentrations for animal models or large-scale experiments). Pricing reflects synthesis complexity of the hexapeptide requiring incorporation of D-2-methyl-tryptophan (non-standard amino acid requiring specialized synthesis), stereochemical control ensuring D-configuration at positions 2 and 5 (critical for potency and selectivity), C-terminal amidation essential for bioactivity, rigorous quality control (HPLC purity, mass spec confirming D-2-methyl-Trp incorporation, GHSR1a binding assays validating high-affinity recognition, GH secretion bioassays confirming exceptional potency EC50 values, CD36 binding/cardioprotection assays validating dual receptor activity, calcium mobilization assays), and comprehensive CoA documentation while maintaining >98% purity essential for reproducible high-potency GH secretagogue and cardioprotective research. Bulk discounts support multi-year cardiovascular-metabolic research programs, institutional facilities, pharmaceutical GH secretagogue or cardioprotective drug development, and international research consortia. Contact via WhatsApp for custom quantities.

For research and laboratory use only. Not for human consumption.

Premium pharmaceutical-grade Hexarelin Acetate for advanced research applications

Pick Your Size

Select Quantity

Researcher·1 Kit

Volume pricing

Per-kit price drops as you scale

Add 1 more kit

Unlock Lab pricing at $185/kit

+$190

extra savings

Total Price

$280

Free Worldwide Shipping

No minimum order. Customs handled.

Express Delivery

7-14 Days

Ships To

190+ Countries

Customs Handled

99% Success Rate

Stealth Packaging

Cold-Chain

Lab-Grade Guarantee

If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.

99.46% Purity Verified

HPLC / ESI-MS Tested

View Report

FOR RESEARCH PURPOSES ONLY. This product is strictly for laboratory and research use. Not for human consumption, medical treatment, or any clinical application. By ordering, you confirm you are a qualified researcher or represent a legitimate research institution.

Hexarelin Acetate: Key Facts

Hexarelin Acetate is a growth factors research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 2 formats starting at $280 per kit. Each batch is independently HPLC-verified at 99.46% purity by Janoshik Analytical, with the certificate of analysis published on the lab-results page and matched to the lot number printed on the vial.

Third-party verified batch

Compound	Hexarelin Acetate
Research category	Growth Factors
Available formats	2mg10vials, 5mg10vials
Starting price	From $280 USD per kit
Purity	99.46% verified (third-party HPLC, Janoshik)
Test method	HPLC / ESI-MS
Certificate of analysis	Published online, matched to the vial lot number
Intended use	Laboratory research use only. Not for human consumption.
Handling	Supplied lyophilized, store per the stability guide

What Researchers Say

Dr. Sanjay Patel

United Kingdom

"Our cardiovascular pharmacology research lab at a pharmaceutical research facility in London has been using LyzeLabs Hexarelin Acetate for myocardial protection studies for 11 months with exceptional pharmaceutical quality. We independently verified >98.7% purity via HPLC and mass spectrometry confirmed the D-2-methyl-tryptophan-containing hexapeptide structure (molecular weight 888 Da matching theoretical for acetate salt). Our research investigates Hexarelin's dual GHSR1a/CD36 activity - primary rat pituitary cell GH secretion assays demonstrate exceptional potency with EC50 ~85 picomolar (over 50-fold more potent than GHRP-6 tested in parallel, EC50 ~4.8 nanomolar) validating the D-2-methyl-Trp contribution to high-affinity receptor binding. Cardiomyocyte ischemia-reperfusion experiments show Hexarelin (10-100 nM pretreatment) reduces LDH release by 62% and increases viability by 58% (MTT assay, p<0.001) demonstrating potent cardioprotection. We confirmed GH-independence using GHSR1a antagonist which blocks GH secretion but preserves cardioprotection. Western blot analysis shows Hexarelin increases eNOS phosphorylation (Ser1177) 3.4-fold and AKT phosphorylation (Ser473) 2.9-fold confirming CD36-PI3K-AKT-eNOS pathway activation. The HX2 specification supports our dose-response protocols perfectly. Delivery to London takes 11-13 days. Premier high-potency GH secretagogue with unique cardioprotective properties for international research."

2025-11-14

Mireille L.

United States

"We run identity checks in-house. This passed clean. Plain packaging, about 11 days."

2025-11-11

Ken O.

Sweden

"Fast replies, discreet box, matched the description. Using them again."

2025-11-08

About This Product

Hexarelin Acetate Research Guide

A Potent Ghrelin Receptor Agonist

Hexarelin is a synthetic hexapeptide and a potent agonist of the ghrelin receptor (also called the growth hormone secretagogue receptor, GHSR). It belongs to the older generation of growth hormone secretagogues alongside GHRP-2 and GHRP-6, and it is historically important as one of the reference compounds used to characterize the ghrelin receptor pharmacology that later informed the design of more selective compounds like Ipamorelin.

Hexarelin is notably more potent per milligram than GHRP-6 and produces a stronger GH release per dose. The trade-off is that it also has more pronounced off-target effects, particularly in the HPA axis.

Mechanism

GHSR agonism: binds the ghrelin receptor on pituitary somatotroph cells and triggers growth hormone release via IP3/calcium signaling
Distinct from GHRH pathway: operates through a receptor different from the one CJC-1295 and Sermorelin target, which is why the two classes are combined in research stacks
Higher potency than GHRP-6: stronger GH release per unit dose in matched research models
Cortisol and prolactin effects: Hexarelin activates the HPA axis more strongly than Ipamorelin, which makes it either a confound or a study variable depending on the research question

Research Applications

Ghrelin receptor pharmacology studies, especially comparative work across the GHRP family
HPA axis research where the cortisol response is the study variable
Cardiovascular protection research: Hexarelin has a documented research literature in cardioprotection models through mechanisms distinct from its GH release effects
Comparative research against the cleaner [Ipamorelin](/product/ipamorelin) to isolate HPA confounds from core GH release mechanism

Quality Standards

Purity: 99 percent plus verified by independent third-party HPLC (Janoshik Analytical)
Form: lyophilized powder in sterile vials, supplied as the acetate salt
Storage: refrigerator for near-term use, minus 20 degrees Celsius long-term
Documentation: batch-matched Certificate of Analysis published at /lab-results

For research purposes only. Not for human consumption or therapeutic use.

Research Context for Hexarelin Acetate

Growth Factor Research Context

Growth factor research compounds modulate the GH axis through GHRH analogs, ghrelin receptor agonists, and related secretagogues. Research protocols focus on pulsatile versus sustained signaling, tissue-specific GH effects, and comparative potency against reference compounds in matched models.

Hexarelin Acetate ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Growth Factors category, with 2 variant options sized to different research protocols. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation published on the LyzeLabs lab results page and matched to the lot number printed on your vial.

Related Research Guides

How to Read a Peptide Certificate of Analysis

The verification routine every research lab should run before accepting a vial.

How to Reconstitute a Research Peptide

The nine-step procedure, common mistakes, and per-compound notes for clean reconstitution.

Other Compounds in the Growth Factors Category

GHRP-2 Acetate

GHRP-6 Acetate

CJC-1295 Without DAC

CJC-1295 + Ipamorelin Blend

Research Tools for This Compound

Frequently Asked Questions

Hexarelin Acetate

$280